NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.54 CHF | +0.85% |
|
+1.88% | +6.68% |
| May. 06 | NOVARTIS AG : UBS maintains a Buy rating | ZD |
| May. 02 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
ETFs positioned on Novartis AG
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | 0.00% | - | |
| 0.00% | 0 M€ | -1.79% | - | |
| 0.01% | 0 M€ | -2.11% | - | |
| 0.01% | 0 M€ | -2.79% | - |
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
99
USD
Average target price
108.4
USD
Spread / Average Target
+9.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.68% | 202B | |
| +33.29% | 700B | |
| -4.93% | 358B | |
| +19.03% | 330B | |
| +3.40% | 287B | |
| +15.70% | 236B | |
| -9.08% | 197B | |
| +5.52% | 161B | |
| -2.19% | 157B | |
| +3.70% | 124B |
- Stock Market
- Equities
- NOVN Stock
- Funds and ETFs Novartis AG